PHOSPHOLIPIDS AND PHOSPHOLIPID METABOLITES FOR TREATING VIRAL AND BACTERIAL PNEUMONIA AND SEPSIS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 20, 2023
app pub date -
Apr 16, 2021
filing date -
Apr 17, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The invention relates to lyso-phosphatidylcholine (LysoPC), or a suitable precursor or derivative thereof, or a composition containing LysoPC and/or one or more suitable precursors or derivatives thereof, for use in the treatment and aftercare of inflammatory diseases in humans that involve lowering of the LysoPC level, including the treatment, prevention or support of treatment and aftercare of viral and bacterial pneumonias and sepsis, including pneumonia and sepsis as a consequence of influenza, Covid-19, ARDS, cancer, for supporting immunotherapy in cancer in view of effectiveness and for reducing side-effects, such as pneumonitis, colitis or hepatitis, and for reducing undesirable vaccination responses. The invention further relates to alpha-glycerophosphocholine (alpha-GPC), or a variant thereof, or a composition containing alpha-GPC and/or one or more variants thereof, for use in the treatment and aftercare of cancers and tumor cachexia.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully